Navigation Links
New Drug Approved for Treatment of Non Small Cell Lung Cancer in Specific Patient Population
Date:9/1/2011

WASHINGTON, Sept. 1, 2011 /PRNewswire-USNewswire/ -- Lung Cancer Alliance (LCA) applauds the Food and Drug Administration (FDA) approval of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) who are ALK positive.  The drug was approved based on data from two clinical trials, both of which showed a significant increase in overall survival.  

Xalkori targets the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) mutation. According to the FDA, the mutation is only present in 1-7% of people with NSCLC, primarily those diagnosed with adenocarcinoma.

"This is exciting news," said LCA President & CEO, Laurie Fenton Ambrose.  "Personalized medicine is where we are headed for lung cancer treatments.  This is one of the first steps towards identifying medications that help select populations of people.  We must continue to identify other mutations and find drugs that treat them to finally see cures for lung cancer." 

"I was enrolled in the phase I trial for this drug," said Linnea Duff, NH resident and longtime lung cancer survivor.  "At the time I began the trial, I was hoping to have my life extended for a few months. Instead, I got three more years to spend with my family and friends. In addition, because this was a targeted therapy, the side effects were minimal and my quality of life during this time has been remarkable."

Xalkori has shown a life changing response to lung cancer in those patients who are ALK positive.  Lung Cancer Alliance encourages lung cancer patients to discuss genetic testing options with their health care team.  

It is important to note that many genetic mutations have been identified but not all have drugs to target the mutations at this time. With continued focus from researchers and increased participation in clinical trials, more and more of these personalized therapies will become available.  


'/>"/>
SOURCE Lung Cancer Alliance
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Unapproved Emergency Birth Control Medicine Possibly in U.S. Distribution May Be Ineffective and Unsafe
2. Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
3. Shire plc: Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
4. Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
5. TandemHeart Approved for Expanded Reimbursement
6. Breast Cancer Patients and Families Decry FDA Panel Vote to Remove Life Saving Drug From Approved List
7. Laureates Electronic Submission Gateway Approved
8. Capacity Constraints Continue to Loosen for Suzhou Erye Pharmaceuticals as a New Production Line is Approved by the China SFDA
9. Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatisms Congress
10. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
11. FDA Expands Approved Use For Carotid Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a ... diseases and cholesterol gallstones, announced today that the ... approved its request for Fast Track Designation of ... Non-Alcoholic Steato-Hepatitis, or NASH.  FDA ...
(Date:9/23/2014)...  SiteOne Therapeutics Inc. today announced the completion of ... Capital Management and Biobrit LLC, with additional investors Mission ... million financing positions SiteOne to advance its oral Na ... develop its technology platform for long-acting local analgesics, pain ... with the financing, Lowell Sears (Sears Capital ...
(Date:9/23/2014)... Sept. 23, 2014  KemPharm, Inc., a clinical-stage ... development of proprietary new molecular entity (NME) prodrugs, ... Letter (NOL) from Health Canada to begin clinical ... its lead product candidate KP201 (benzhydrocodone hydrochloride and ... for acute moderate to moderately severe pain. The ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3
... PXS) today announced significant results of pooled data from ... of Bronchitol (inhaled mannitol) in people with cystic fibrosis. ... the first time at the North American Cystic Fibrosis ... results from the second trial (CF302) have been released ...
... Oct. 22 INVO Bioscience, Inc. (OTC Bulltin Board: ... for patients diagnosed with infertility, today announced that Dr. ... (CECOFLES LTDA) will present the results of the first ... INVO Bioscience,s INVOcell technology at the 66th Annual Meeting ...
Cached Medicine Technology:Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 2Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 3Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 4Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 5INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine 2INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine 3
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 ... weights, breast milk is more likely than a blood transfusion ... (CMV), a new study finds. The researchers evaluated more ... whom weighed 3.3 pounds or less and many who were ... see whether breast milk or transfusions carried the bigger risk. ...
(Date:9/23/2014)... San Francisco, CA (PRWEB) September 23, 2014 ... search for original 1967 The Doors Eagle Auditorium Seattle concert ... of their album “Break On Through” that year. The Seattle ... According to Hawley, “The Doors would return to Eagles Auditorium ... Doors July poster is not known and comes in three ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- The number of ... drugs is growing, so doctors need to be ... Drug Administration warned Tuesday. In a statement, ... that it has launched a program to educate ... about proper drug purchasing procedures. The program aims ...
(Date:9/23/2014)... Vancouver Electrician Contractors, Pro Ace, has ... electrical services in Vancouver, BC. The company will provide ... a small maintenance project or a large-scale new installation ... meet the needs of the individual commercial client. Pro ... of an affordable price. As a result, businesses of ...
(Date:9/23/2014)... September 23, 2014 The University ... research university located In the Piedmont Triad, announced ... as co-director of the Center for Translational Biomedical ... comes to UNCG after nearly a decade at ... Laboratory, Biological Sciences Division. , “Our goal ...
Breaking Medicine News(10 mins):Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Pro Ace Now Offers Commercial Electrical Services in Vancouver 2Health News:Former Department of Energy Scientist Joins UNCG as Co-director of Biomedical Research Center 2
... improve the effectiveness of the only tuberculosis vaccine approved ... in a pre-clinical test, report scientists at The University ... Nature Medicine ,s Advance Online Publication March 1. Their ... funded by the National Institutes of Health (NIH). ...
... Medical Event Available from the Convenience of a Computer, www.CardioCareLive.com ... from 9:30 AM to 8:00 PM Eastern.,Patch Adams, MD, the real ... speak. To register now for free, visit cardioCareLive.com. , ... ...
... American Public Health Association,s (APHA) new Fluoridation Position ... support nor evaluate fluoridation,s safety and/or effectiveness as ... Fluoridation, Inc. APHA asserts, "All of these reviews ... safe and effective." Here,s the truth about APHA,s ...
... drug-eluting stentNATICK, Mass., March 3 Boston Scientific ... the launch of its TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary ... approved on January 28 by the Ministry of ... yesterday by the National Health Insurance System.TAXUS Liberte ...
... patients, the soles of their feet and the palms of ... because of some types of chemotherapy. Patients, family members also ... , Both share a need for quick answers or ... diagnosis, treatments, or unexpected symptoms. , A new section ...
... to Defend His TitleNORTHRIDGE, Calif., March 3 There ... names, two decks of shuffled playing cards, or a ... minutes. Chester Santos, the 2008 USA National Memory Champion, ... when he defends his title at the USA National ...
Cached Medicine News:Health News:TB breakthrough could lead to stronger vaccine 2Health News:TB breakthrough could lead to stronger vaccine 3Health News:CardioCareLive, First-Ever Online Cardiometabolic Conference, Debuts Today 2Health News:APHA Misleads Americans About Fluoridation 2Health News:Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System 2Health News:Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System 3Health News:Walther Cancer Foundation grant funds new IU Simon Cancer Center Web site section 2Health News:The Making of a Memory Champion 2Health News:The Making of a Memory Champion 3
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
... of both worlds, the PeaceKeeper 20 ... latest addition to the Wet-Field comprehensive ... instruments for ophthalmic surgery. Combining highly ... and backflush functionality in a single ...
...
...
Medicine Products: